2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation
2013
Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases
Izu A, Cohen T, DeGruttola V. Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases. PLOS Computational Biology 2013, 9: e1002973. PMID: 23555210, PMCID: PMC3605089, DOI: 10.1371/journal.pcbi.1002973.Peer-Reviewed Original ResearchConceptsTreatment-experienced patientsDrug-resistant strainsMultiple drug-resistant strainsTreatment-naïve patientsDrug-resistant tuberculosisMycobacterium tuberculosis isolatesWorld Health OrganizationDrug resistance pathwaysTreatment-naïveTuberculosis casesTuberculosis isolatesWorldwide surveillanceDrug resistancePatientsHealth OrganizationResistant strainsResistant pathogensResistance pathwaysLow transmissibilityPathwayTuberculosis